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Introduction
The dawn of the 21st century brought about a critical turning point 
in our understanding of the molecular basis of cancer and the 
potential to translate cancer genetics discoveries into therapeutic 
advances. The dramatic efficacy of imatinib in the treatment of 
Philadelphia chromosome–positive chronic myelogenous leukemia 
(CML) (1, 2), as well as the recognition that activating mutations in 
EGFR predict the therapeutic response of patients with non–small-
cell lung cancer (NSCLC) to EGFR inhibitors (3, 4), were thought 
to be harbingers of a time when targeted therapy could be paired 
with genomic information to identify responsive patients and, 
effectively, personalize medicine. While additional success stories 
exist, cancer is a complex disease, and the envisioned tsunami of 
the genomic revolution has taken time to reach shore.
Cancer researchers have benefited tremendously from the 
advent of high-throughput sequencing. The genomes of thou-
sands of tumors have now been sequenced both by individual 
groups and through collective efforts such as the International 
Cancer Genome Consortium (ICGC) and The Cancer Genome 
Atlas (TCGA) (1, 2, 5). At the same time, there has been an explo-
sion in the development and clinical testing of targeted agents (6, 
7). Therefore, two of the fundamental building blocks of an effec-
tive genomics-driven oncology program are now available. While 
conceptually the integration of genomics-driven oncology into 
clinical practice would seem straightforward, its implementation 
has proven to have real-world complexities such as the unintended 
discovery of germline variants of unknown significance, the sparse 
amounts of archival tumor tissue, the difficulty of establishing the 
biologic significance (or “actionability”) of somatic events, and 
the translation of a cohesive and accurate depiction of the genomic 
portrait of a tumor to treating physicians and their patients. As we 
strive to integrate next-generation (next-gen) sequencing technol-
ogy into clinical medicine, forethought about desired outcomes, 
technical and ethical considerations, and a structured multidisci-
plinary plan will be needed to extract the most beneficial informa-
tion from the large amounts of data and genomic results produced.
Actionable events
High-throughput sequencing techniques have now evolved to the 
point where cancer genomes can be sequenced quickly, sensitively, 
and accurately. Data from ongoing research initiatives such as the 
ICGC and the TCGA have demonstrated that the mutation rates 
vary greatly between tumor types (from 0.28 to 8.15 mutations per 
megabase in acute myeloid leukemia [AML] and lung squamous 
carcinoma, respectively), as does the mutational spectrum (8). 
Some cancers also exhibit significant intratumoral heterogeneity 
(9). Viewed broadly, these findings show that cancer genomes are 
convoluted and harbor both driver and passenger mutations.
At this juncture, the cost of high-throughput sequencing is eas-
ily within reach of academic medical centers. Furthermore, stan-
dard operating protocols (SOPs) have been developed to ensure 
reproducibility of results with validation in clinical laboratory 
improvement amendment–certified (CLIA-certified) settings. 
Therefore, the current bottleneck in delivering genomics-based 
cancer medicine is rarely data generation, but rather results inter-
pretation, validation, and determination of actionability. If the 
overarching hypothesis of genomics-driven oncology is that the 
genomic landscape of tumors can be converted into actionability 
maps or an “actionability atlas,” as we have chosen to call it, then 
the careful cataloging of genomic variants and their resultant 
ability to predict prognosis or treatment response is imperative. 
Much like the Catalogue of Somatic Mutations in Cancer (COS-
MIC) contains a comprehensive catalog of over 136,000 somatic 
coding mutations in over 500,000 tumor samples, we predict 
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low (tier 1 lists those currently defined as actionable at the Uni-
versity of North Carolina at Chapel Hill [UNC] using our next-gen 
sequencing platform UNCseq) (Tables 1 and 2). Nonetheless, a 
careful, prospective cataloging of genomic results and a more 
pathway-driven (as opposed to organ site–driven) approach to 
therapy will likely lead to a more expansive, yet refined, list of clin-
ically actionable events.
To date, the vast majority of targeted therapy successes are 
small-molecule kinase inhibitors. While these stories tell us that 
such inhibitors can be used successfully to treat cancers driven by 
specific molecular events, whether such precision targeting can be 
achieved outside the realm of kinases remains to be seen. Exciting 
examples of inhibitors of other enzymatic reactions, such as inhibi-
tion of the H3K79 methyltransferase DOT1L in mixed-lineage leu-
kemia (MLL), rearranged acute leukemias, or the isocitrate dehy-
drogenase 1 and 2 (IDH1/2) enzymes in IDH-mutant malignancies 
(i.e., glioblastoma and AML), have entered clinical trials and shown 
initial indications of effectiveness in both early-stage clinical trials 
and preclinical models (17–20). In addition, the enhanced sensitiv-
ity of BRCA1/2-deficient cancers to poly(ADP-ribose) polymerase 
(PARP) inhibition suggests that targeted therapies might be used to 
target tumor-suppressor gene loss as well (21).
Communication of results to clinicians: 
molecular tumor boards
A key step in the infrastructure of genomics-based oncology is the 
communication of genomic alterations to treating physicians and 
their patients.
At UNC, we have chosen to stratify genomic alterations based 
on their likelihood of clinical actionability. Molecular alterations 
that are considered standard of care (SOC), for example, EGFR or 
KRAS testing in NSCLC and CRC, respectively (22, 23), are readily 
determined to be both actionable and reportable. The majority of 
oncologists also have a good understanding of the clinical implica-
tions of the results. These alterations are considered tier 1 (Tables 
1 and 2). A second, more challenging group of genomic alterations, 
tier 2, involves genetic alterations of potential clinical significance; 
for example, a previously reported mutation that is detected in 
a class of tumors in which it has not been reported (e.g., EGFR 
mutations in bladder cancer). This list can be further stratified by 
whether the targeted drug(s) is commercially available (tier 2A), in 
clinical trials (tier 2B), or not yet in clinical trials but the target is still 
considered druggable (tier 2C). Finally, genetic alterations that are 
considered to have prognostic value are reported as well (tier 2D).
The assignment of genetic alterations to the above categories 
is relatively straightforward for previously reported variants or 
copy number alterations that have been compiled into online data-
bases such as COSMIC. More challenging is the attribution of clin-
ical actionability to variants of unknown significance (i.e., those 
that have not been previously been reported) in known oncogenes 
or tumor-suppressor genes or to variants clearly altering the func-
tion of genes that have not been implicated previously in cancer. 
We have found it useful to discuss these cases and generate a 
framework for decision making at a so-called “molecular tumor 
board” (MTB) composed of clinical and translational oncologists, 
molecular pathologists, and bioethicists. Within these tumor 
boards, decisions about the actionability of genomic events and 
that the effectiveness of genomics-based oncology will rely on an 
operative database linking somatic mutations to therapeutic suc-
cesses or failures (10).
So what attributes make a genomic event clinically actionable? 
While clearly investigator dependent, we propose some common 
basic tenets. First, the alteration in a gene or pathway should be 
clinically informative, either at the level of diagnosis (e.g., muta-
tion of the von Hippel–Lindau tumor-suppressor gene is specific 
for the clear-cell histologic subtype of renal cell carcinoma; ref. 
11), prognosis, or for the prediction of treatment response (e.g., 
EGFR inhibition in EGFR-mutant NSCLC; refs. 3, 4, 12) or resis-
tance (e.g., KRAS mutations confer resistance to EGFR inhibition 
in colorectal cancer [CRC]; refs. 13–16). Second, there should be 
precedent (preferably in the specific tumor type) that the somatic 
event is a driver mutation. Finally, the genetic aberration should 
optimally be druggable in a specific manner. Based on these strict 
criteria, the number of truly actionable mutations is surprisingly 
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respectively, serve as proof of principal that biomarker profiling 
can occur in real time and that adaptive trial design can validate 
prespecified hypotheses (32, 33). Nonetheless, additional ran-
domized, controlled studies are needed to further confirm the 
true predictive value of the biomarkers studied in those trials. 
Finally, it will likely take some work to define the optimal next-gen 
biomarker cutoff points for results other than canonical muta-
tions. In the BATTLE and I-SPY2 trials, many of the prespecified 
biomarker cutoffs were based on a wealth of past clinical experi-
ence (e.g., ER and HER2 immunohistochemistry) accumulated 
the necessity of CLIA confirmation are made by consensus. None-
theless, in a reasonable fraction of detected variants of unknown 
significance, the decision to validate and report remains some-
what arbitrary (Figure 1).
Integration of next-gen sequencing into clinical 
trials
If discrete genetic alterations can truly predict therapeutic vul-
nerabilities, then next-gen sequencing of tumors should allow 
either the prospective identification and enrichment for poten-
tial responders or the retrospective evaluation to identify genetic 
features associated with response or resistance to therapy. The 
ability to perform continual mining of data after their initial use 
for treatment choice is of particular import, as novel therapies are 
approved for use and as we gain additional knowledge about the 
utility of genomic biomarkers. Additionally, an unintended con-
sequence of next-gen sequencing of cancer genomes is likely to 
be a shift from clinical trials based on organ site to those that are 
based on alterations in oncogenic pathways (Figure 2). An exam-
ple of this is the treatment of BRAF-mutant cancers with MEK 
or BRAF inhibitors in multiple tumor types such as melanoma, 
CRC, thyroid, and urothelial carcinoma (24–27). Nonetheless, it is 
important to proceed with caution, as genomic alterations may be 
exquisitely context specific. For example, recent clinical trials have 
shown that BRAF-mutant melanomas are highly sensitive to BRAF 
kinase inhibitors (vemurafenib) (28), as are BRAF-mutant papil-
lary thyroid cancers. Thus, many oncologists were surprised when 
BRAF-mutant CRCs were found to be less responsive to vemu-
rafenib (29). Careful laboratory studies have since revealed that 
this relative resistance to BRAF inhibition in CRC is secondary to 
compensatory upregulation of EGFR signaling, which in preclini-
cal models can be cotargeted with PI3K/AKT pathway inhibitors 
(30, 31). These findings underscore the danger in generalizing 
therapeutic vulnerabilities across all tumors and demonstrate the 
importance of validating targets in the context of individual tumor 
types (Figure 2). Therefore, while it is tempting to imagine a brave 
new oncologic world in which tumors are categorized by driver 
pathway alterations rather than organ site, cancer is complex, and 
this simplistic view will need refinement.
While not based on a next-gen sequencing platform, several 
large, adaptively randomized trials using molecular biomarkers, 
such as BATTLE (biomarker-integrated approaches of targeted 
therapy for lung cancer elimination) and I-SPY2 TRIAL (investi-
gation of serial studies to predict your therapeutic response with 
imaging and molecular analysis 2) for NSCLC and breast cancer, 
Table 2. Categorization of UNCseq genomic alterations
Tier Reported Definition
1 Yes Variation targeted by commercially available drug that is approved to treat this genetic variation
2A Yes Variation potentially treatable by commercially available targeted drug, but drug not indicated for this use
2B Yes Variation potentially treatable by targeted drug that is in clinical trials
2C No Variation potentially treatable by targeted drug, but no targeted drug has reached the clinic
2D No Variation of prognostic significance
 
Figure 1. Genomics-based oncology workflow and integration of an 
actionability atlas. The sequencing of cancer genomes requires coordinated 
efforts and constant modification. Patients are consented to access archi-
val tumor tissue or fresh tumor tissue obtained from a new biopsy. Genomic 
profiles are generated by next-gen sequencing of tumor and normal (germ-
line) tissues and are discussed at MTBs. The decision to report variants 
back to the patient and physician is made by consensus at the MTB in part 
based on a categorization of genes predetermined by an independent panel 
of clinical experts (the Clinical Committee for Genomic Research [CCGR]). 
Potential outcomes of the reporting of an actionable variant include: 
enrollment in a clinical trial, off-label use of a current FDA-approved agent, 
or continued SOC treatment. Systematic cataloging of outcomes into a 
proposed actionability atlas should aid future decision making.
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but have also defined dramatic changes in 
histologic subtypes (i.e., a therapy-driven 
switch between NSCLC and small-cell 
lung cancer) (37). Therefore, for genom-
ics-based oncology to fully achieve its 
promise, a genomic snapshot of a patient’s 
tumor requires repeated updates.
Circulating tumor DNA. While the nex-
t-gen sequencing of cancer genomes has 
traditionally been performed on banked tis-
sue (either fresh-frozen or formalin-fixed, 
paraffin-embedded [FFPE]), it has recently 
been applied to detect circulating tumor 
DNA (ctDNA) in the peripheral blood of 
cancer patients. Beyond the obvious ease of 
sample acquisition (phlebotomy rather than 
obtaining archival tumor tissue or a new 
biopsy), the next-gen sequencing of ctDNA 
is likely to serve a number of broader appli-
cations. For example, recent work suggests that it can be used to 
noninvasively monitor tumor burden (38–40) and, perhaps most 
excitingly, that it can be used to detect mechanisms of secondary 
resistance to targeted therapy (e.g., activation of the RAS/MEK/
ERK pathway in EGFR inhibitor–treated metastatic CRC patients) 
(40, 41). While not prohibitive, a current limitation to most of the 
reported ctDNA techniques is the need for relatively deep and 
broad sequencing of putative ctDNA.
Tumor microenvironment. Harnessing the immune system for 
cancer therapy has undergone a recent renaissance. Impressive 
therapeutic outcomes have been observed across several immu-
notherapy platforms, including adoptive cellular therapy (e.g., 
chimeric antigen receptors [CARs] in hematologic malignancies) 
(42–46), immune checkpoint blockade (e.g., anti–PD1/PD-L1 
antibodies in numerous solid tumors) (47, 48), and various tumor 
vaccination strategies (49–51). This has led to an intense search for 
predictive biomarkers of immune responsiveness. While intratu-
moral expression of PD-L1 has been proposed to have a high neg-
ative predictive value for the efficacy of anti–PD-L1 therapy (48), 
additional biomarkers are under active investigation.
Unfortunately, next-gen sequencing of bulk cancers does not 
capture important information on the immune infiltrate, such 
as the level of immune cell infiltration or the cellular milieu of 
immune cells present, which may be important biomarkers of not 
only response to immunotherapy but also to cytotoxic chemo-
therapy (52, 53). Nonetheless, recent studies confirm the utility of 
exome sequencing for discovery of tumor neoantigens, although 
it should be noted that the majority of neoantigens identified are 
in genes that are absent in current targeted exon–sequencing pan-
els (54, 55). Overall, it seems likely that the integration of other 
genomic platforms such as RNA sequencing and platforms such 
as proteomics and polychromatic flow cytometry will allow for a 
more comprehensive “immune portrait” of tumors, including 
the molecular assessment of lymphocyte clonality and diversity 
(56) as well as the assessment of other key microenvironmental 
components such as tumor-associated fibroblasts and endothelial 
cells, which may be key predictors of response to both immune 
and antiangiogenic therapies (refs. 57, 58, and Figure 3).
over decades (32, 33). Nevertheless, the integration of next-gen 
sequencing into prospective clinical trials is a reality and, when 
performed rigorously, will likely yield immense value.
Unresolved issues
Tumor heterogeneity and the development of resistance. High-reso-
lution tumor-sequencing studies have now defined the startlingly 
broad scope of intratumoral genomic heterogeneity, which likely 
contributes to treatment failure as well as the development of drug 
resistance (34). In retrospect, intratumoral heterogeneity should 
not have been unexpected, since pathologists have for decades 
remarked on the variant histologic differentiation that can coex-
ist within what appears to be a solitary tumor. Genomic variability 
has clear implications for genomics-driven oncology, as genomic 
characterization of tumors (at least for solid tumors) is typically 
made from a limited tumor sampling and therefore likely rep-
resents only a small percentage of the genomic diversity within 
a tumor. Furthermore, genomic heterogeneity is not limited to 
primary tumors, but is clearly an attribute of metastases (35). 
Therefore, it seems likely that genomics-based oncology will con-
tend with intratumoral heterogeneity and the limited sampling of 
tumor tissue as intrinsic considerations. While shared mutations 
should be easily annotated, the detection of private mutations will 
be dependent on the lesion sampled.
Clinical responses to targeted therapy can often be dramatic 
(e.g., EGFR-mutant lung cancers and response to erlotinib; refs. 
3, 4), yet treatment with targeted therapy invariably results in the 
development of drug resistance, presumably through positive 
selection for rare subclonal cell populations within the primary 
tumor harboring secondary mutations, activation of downstream 
effectors, or activation of a bypass oncoprotein (36). In the current 
paradigm of genomics-based oncology, a single genomic snapshot 
of a patient’s tumor is taken, with all future actionability decisions 
made on that single sample; however, recent studies demonstrate 
the value of performing rebiopsies of tumors at the time of clinical 
progression on targeted therapy (37). Such studies have defined 
novel mutations that reduce the efficacy of kinase inhibitors (i.e., 
T790M mutations in NSCLC treated with EGFR kinase inhibitors) 
Figure 2. Integration of pathway and organ site clinical trials. (A) Current oncology clinical trials are 
generally structured based on organ site, in which novel compounds (A, B, and C) are tested in spe-
cific cancers. (B) There are, however, commonalities in oncogenic pathways among cancers such as 
activation of the EGFR, FGFR3, and BRAF pathways. These pathways can be targeted with relatively 
specific inhibitors (X, Y, and Z). Some clinical trials are beginning to enroll patients on the basis of 
pathway activation (i.e., FGFR or BRAF mutations). (C) This approach, while reasonable, will likely 
require attention to both pathway activation and organ site. For example, BRAF mutations are found 
in a number of cancers including melanoma, thyroid, colon, and bladder. While BRAF inhibition has 
shown efficacy in BRAF-mutant melanoma and thyroid cancer, it does not appear to benefit patients 
with BRAF-mutant CRC. Whether BRAF inhibition in bladder cancer is of use remains unknown.
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perceived level of genomic confidence, with approximately 22% 
of surveyed physicians reporting that they were “not very confi-
dent” or “not confident at all” in their knowledge of genomics. 
These findings reiterate that vehicles for consensus such as mul-
tidisciplinary MTBs and evidence-based guidelines are key com-
ponents to a successful genomics-driven oncology program. It will 
be of interest to assess similar perceptions in community-based 
oncology practices where, at least to our knowledge, genomics 
tumor boards are not part of routine practice.
The next steps
At many academic medical centers, the building blocks for genom-
ics-driven oncology are now in place. In reality, this has been rela-
tively easy, as capital expenditure to purchase next-gen sequenc-
ing machines and reagents is merely a line item on a cancer 
center’s annual budget. It seems that the coming years will be the 
most difficult, for to truly benefit, patients will depend on the use 
of human capital for data processing, the timely interpretation and 
reporting of actionable results, and, perhaps most importantly, the 
effective communication about the implications of these results to 
patients. Indeed, we can sequence as many cancer genomes as 
we like, but without talented bioinformaticians to decipher the 
data and so-called “genomic navigators” to guide us, the clinical 
actionability of unannotated variants remains questionable.
Genomics- or “omics”-driven oncology? The value of bioin-
formaticians is likely to increase exponentially, as genomics-
driven oncology expands to encompass platforms outside of 
DNA-based mutations and gene copy number alterations. The 
future of genomics, or perhaps more appropriately, “omics”-
Issues of reimbursement. Despite the increasing enthusiasm for 
integrating genomics into cancer care and its promise to advance 
personalized therapy, there are obvious economic consequences. 
In general, economic analyses consider the health gained relative 
to the resources expended, which can be measured by various 
metrics such as incremental cost–effectiveness ratios (ICERs) or 
quality-adjusted life years (QALYs) (59). In one analysis, EGFR 
mutation testing to predict response to EGFR inhibitor treatment 
in the first-line treatment of metastatic NSCLC showed that it is 
cost effective, with an ICER of $81,071 per QALY or $46,021 per 
life year (60). Studies such as these suggest that the integration of 
next-gen sequencing into cancer care may have a positive impact 
on health-care economics. Nevertheless, future studies will be 
required to fully define the economic consequences of technology 
with both well-defined costs (i.e., the price of actual sequencing) 
and the less-well-defined expenditures on personnel for data pro-
cessing, secure data storage, variant interpretation, and determi-
nation of actionability at MTBs.
Oncologists’ perception. It is undeniable that the next-gen 
sequencing of cancer genomes has become widespread as well as 
commercialized (e.g., FoundationOne), suggesting that physicians 
have confidence in the technology and process as well as comfort 
in discussing genomic results with their patients. A survey of phy-
sicians at a tertiary care center prior to the rollout of their next-gen 
tumor-sequencing platform, however, revealed that there was a 
wide variability in how physicians planned to incorporate potential 
results into clinical practice and in their attitudes toward the dis-
closure of variants of undetermined significance (61). As might be 
expected, physician opinion on these topics correlated with their 
Figure 3. Next-gen sequencing and the complexity of human tumors. Next-gen sequencing of tumors delivers a high-resolution snapshot of the genom-
ics of tumor cells. With the exception of whole-exome sequencing, which may help identify tumor neoantigens, it does not generally inform us about the 
tumor microenvironment. Other “omic” platforms, such as RNA sequencing, proteomics and IHC, and polychromatic flow cytometry, would complement 
the current next-gen sequencing platforms, allowing further characterization of tumor cell–autonomous information and also facilitating the generation 
of immune, vascular, and stromal portraits that may have prognostic and predictive value. IF, immunofluorescence.
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driven oncology, likely holds a multiplatform approach that will 
allow comprehensive characterization of a tumor on multiple 
levels; the resulting genomic profile would then be integrated 
with other “omic” data to predict the functional consequences 
of genomic alterations on oncogenic pathways. Thus, our current 
one- or, at best, two-dimensional map of a cancer genome will 
soon transform into a true genomic landscape replete with mul-
tidimensional annotation.
Genomic confidence and genomic navigators. The survey by 
Gray and colleagues suggests that even in tertiary care centers, 
many physicians do not feel confident about their knowledge of 
genomics (61). While not directly surveyed, this low genomic con-
fidence would suggest a relative reticence toward both ordering 
next-gen sequencing of cancer genomes as well as discussing their 
implications directly with patients. Much like medical geneticists, 
who have specialized in the evaluation, testing, and counseling 
of patients with a suspected genetic disorder, it would seem that 
the field of genomics-driven oncology might also usher in a new 
cadre of genomic navigators. The role of these genomic naviga-
tors might be to shepherd patients through the process of testing 
as well as the potential complications of testing (e.g., detection of 
a suspected germline variant). Ultimately, however, discussion of 
the relative actionability of a genomic variant and whether to forgo 
SOC treatment for a personalized therapy will require significant 
input from the treating oncologist.
Development of an actionability atlas. While the future of 
genomics-driven oncology holds much promise, the human 
genome is vast, and the majority of cancer genomes are likely to 
harbor somatic variants of unknown significance. To continue to 
move the field forward rationally, it is imperative that we develop 
a central repository such as the above-proposed actionability atlas 
to catalog novel variants, their purported actionability, and, if 
attempted, their response to therapy. This should be easy in the 
context of clinical trials, but will take a concerted effort as more 
case reports or so-called “N-of-1” studies are undertaken. Despite 
the catchy name, these N-of-1 studies are to some extent case 
reports and remain anecdotal. Moreover, while many N-of-1 stud-
ies are supported by elegant in vitro work backing the genomic 
hypotheses, most clearly require prospective validation or valida-
tion in large, retrospective datasets before widespread adoption in 
clinical practice. Nonetheless, only through the careful cartogra-
phy of cancer genomic landscapes and their responses to therapy 
can we develop an actionability atlas and genetic taxonomy of 
cancer based on both tumor type and genetic makeup.
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